Infinitopes

Infinitopes is an Oxford University spin-out developing a next-generation cancer vaccine platform, termed Precision Immunomics™. The company combines a proprietary antigen discovery engine, which uses laboratory, computational, and machine learning workflows to identify optimal tumor targets, with a novel vector platform designed to induce potent and durable T-cell immunity. With a team experienced in over 70 oncology clinical trials, Infinitopes is accelerating towards a Phase I/IIa trial by the end of 2024, aiming to integrate its vaccines with standard care to improve patient outcomes.

Precision Immunomics™: An integrated platform combining a proprietary antigen discovery engine (using lab, computation, and ML to identify highly-expressed, immunogenic tumor antigens) with a novel vector platform designed to induce potent and durable T-cell immunity.

Infinitopes operates in the highly competitive cancer vaccine/immunotherapy sector, competing with large pharma (e.g., Moderna, BioNTech, Merck) and other biotechs using mRNA, viral vector, and personalized neoantigen approaches. Differentiation hinges on the claimed superiority of its integrated Precision Immunomics™ platform for target selection and immune activation.